Nabla Analysis: $26M Raised
What is Nabla?
Nabla specializes in designing antibodies with atomic precision using integrated AI and experimental technologies. Their unique approach combines AI-guided design with empirical measurement to address complex human biology. This integration enables the development of drugs that are safer, more effective, and easier to manufacture.
Location
Riverside Technology Center, 840 Memorial Dr, Cambridge, Massachusetts 02139, United States
Employees
11-50
Founded
2020
Revenue
$1.2-5M
Funding Status
Seed
Product Features & Capabilities
- de novo antibody design, generative models, multiplexed screens, protein characterization technologies, AI-guided design, wet-lab driven measurement
Use Cases
Design antibodies for challenging disease targets; Measure human-relevant drug properties at scale; Collaborate with pharmaceutical companies for drug development; Enhance manufacturability and safety of drugs; Accelerate drug discovery processes.
Pricing
- Freemium model available with a basic version for free.
- Starter package: $119/month.
- Pro package: $239/month.
- Enterprise package: Custom pricing.
How much Nabla raised
Series A - $26 million
9 months agoLead Investor: AstraZeneca, Bristol Myers Squibb, Takeda
Who are the founders of Nabla
SB
Surge Biswas
Founder
FA
Frances Anastassacos
Founder
HQ Full Address
Riverside Technology Center, 840 Memorial Dr, Cambridge, Massachusetts 02139, United States
Market Focus
Nabla Bio primarily focuses on the biotechnology industry, specifically in the area of drug development through integrated AI and experimental technologies for antibody design.
Investors
- Radical Ventures
- AstraZeneca (strategic collaboration)
- Bristol Myers Squibb (strategic collaboration)
- Takeda (strategic collaboration)
Competitors Overview
Nabla Bio operates in the competitive landscape of AI-driven antibody design and biopharmaceuticals. Its main competitors include:
-
Seismic Therapeutic: This company integrates machine learning into biologics discovery, potentially accelerating immunology drug development through its IMPACT™ platform.
-
AI Proteins: Focused on rationally designing new proteins for therapeutic functions using AI, AI Proteins aims to create innovative protein therapeutics.
-
EVQLV: Utilizing AI to model evolution, EVQLV generates potential biologic therapies rapidly, which may allow for faster development cycles compared to traditional methods.
-
Converge Bio: Employing a generative AI platform for drug discovery, Converge Bio enhances the efficiency and effectiveness of the development process.
-
ImmunitoAI: This startup leverages AI to predict the best therapeutic antibody candidates, claiming to save significant time and costs in the discovery process.
-
Antiverse: Focuses on AI-driven solutions for optimizing therapeutic antibody discovery and engineering.
-
Helixon: Another competitor in the AI antibody design space, focusing on similar technologies.
-
Arctic Therapeutics, Arbor Biotechnologies, and Climax Foods: These companies also operate in the biopharma and biotechnology sectors, focusing on drug development and protein engineering.
Nabla Bio's notable advantages include its unique platform that integrates AI-driven drug design with wet-lab experimentation, allowing for the development of antibodies against challenging disease targets. This collaborative approach with leading pharmaceutical companies may provide Nabla Bio with a competitive edge in the market.
Business Model
Collaborates with pharma to develop and license biologics, generating revenue through partnerships.
See something that needs updating? Suggest edits to this profile.